IMUNON (IMNN) announced that the first trial site has been initiated for the Company’s Phase 3 pivotal study, called OVATION 3, of its lead candidate IMNN-001 in development for the treatment of women with newly diagnosed advanced ovarian cancer. The first trial site is Washington University School of Medicine, and IMUNON is currently initiating additional trial sites and working with investigators to begin enrolling study participants. The Phase 3 OVATION 3 trial will assess the safety and efficacy of IMNN-001 plus neoadjuvant and adjuvant chemotherapy of paclitaxel and carboplatin compared to standard of care N/ACT alone.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMNN:
- Imunon announces data from Phase 1/2 OVATION 2 trial of IMNN-001
- Imunon announces IMNN-001 abstract accepted for oral presentation at 2025 ASCO
- Imunon files to sell 10M shares of common stock, warrants
- Imunon Receives Buy Rating for Strategic Focus and Cost-Effective OVATION 3 Trial
- Imunon finalizes Phase 3 study design with FDA for IMNN-001